Ricky Rivera

Marketing Strategist, Trainor and committed to helping others.

[Ricky Rivera @Ricky72Rivera]

Creating leadership opportunities where talent can shine https://t.co/DDFINhOc9A

[Dr. Hardik Patel 🩺💉 @hardik4u24]

#CKD care is not one-size-fits-all 🧩🩺

From prevention ➝ end-of-life, goals shift:
🟢 guideline-driven therapy
🟡 individualized treatment
🔴 symptom-focused care

Key principle: align #GDMT with life expectancy, function & patient priorities 🤝❤️
https://t.co/jEAWS6ukkV

[Scott Isaacs @scottisaacsmd]

Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3-point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function.
https://t.co/Wzx7dOLTsC

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Obesity‑related glomerulopathy, A growing kidney burden in the obesity pandemic ca. 2025 from @CenJournal @JZRenalPath @Koubar_Sahar @rahaai @SaynaNorouzi
#Nephpearls

👉 https://t.co/49KIwt5Tni

[CORE IM @COREIMpodcast]

1/ 🚨 NEW #WhiteboardAnimation: ILD 🫁

Let’s talk ILD classification & management ⤵️

🎥: https://t.co/mXbQlMWdyX
🖥️: https://t.co/vALUZf34ej

[Aravind Palraj @Rheumat_Aravind]

🫁 ILD – Interstitial Lung Disease
A silent disruptor causing breathlessness, dry cough & fibrosis.

Know the causes (P-I-S-S), patterns (UIP/NSIP), and key treatments.

📍 Early detection in CTDs = better outcome!
#MedTwitter #Pulmonology #Rheumatology #ILD

[Edgardo Alania @Ed_Alania]

🔴 Atrial Fibrillation in the Young: Pathogenesis & Clinical Implications @JACCJournals #Cardiology #Cardioed #Epeeps

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Optimization of Renin-Angiotensin-Aldosterone Inhibitor (RASi) Therapies for Evidence-Based Indications: a Call to Action From the Cardio-Kidney Community ca. 2025 from @KIReports @ISNkidneycare @goKDIGO @RPANephrology @ASPCardio
#Nephpearls #Cardiorenal

👉🏼 https://t.co/qAwveVSqtJ

👉🏼 Toolkit 👉🏼 https://t.co/1ZAyAtIznM

[Brendon Neuen @brendonneuen]

Combination therapy as a new standard of care in CKD - multiple trials testing new therapies in combo with SGLT2i

- ARCTIC/PACIFIC trials: Baxdrostat/dapa vs. dapa
- EASi-KIDNEY: Vicadrostat/empa vs. empa
- ZENITH-HP: Zibotentan/dapa vs. dapa

https://t.co/gxVrfEQDvs

#ERA25

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

IgA Nephropathy (IgAN): Proposed treatment algorithm ca. 2024 from @goKDIGO @IgAN_JBarratt
#ERA25 🇦🇹 #Nephpearls

[Dr sthanu subramanian @drsthanus]

Algorithm for the initial detection and diagnosis of patients with CKD.

https://t.co/OBnGu3rIBh

[Ahmed Bennis MD 🫀 @drbennisahmed]

Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease

Aldostérone synthase inhibitors may emerge as a therapeutic option for patients with Treatment-resistant hypertension

https://t.co/Y0yU8rexqg

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Holistic approach to Non-diabetic CKD and Diabetic Kidney Disease (CKD) from @goKDIGO
#Nephpearls

👉 https://t.co/S8ya3NpzwV
👉 https://t.co/ka7hU7n9eG

[The Heart @ZHeart11768530]

🔴Alteplase (tPA): Indications and dosage in various medical emergencies⤵️

🔹The dose in ischemic stroke is
0.9mg per kg
#Cardiology #FOAMed #MedEd #medstudent #paramedic #Cardiology #CardioEd #medtwitter #meded #CardioTwitter #cardiotwiteros

[Prof Kamlesh Khunti @kamleshkhunti]

Opinion atrticle

SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting
Interesting future Perspective

https://t.co/1YwrjBsvbf

@mmamas1973

[Gregg Fonarow MD @gcfmd]

HFmrEF/HFpEF can’t wait

Rx the 3 🏛️
SGLTi + nsMRA + GLP-1 RA (if obesity)

The optimal strategy is simultaneous or rapid sequence initiation to all eligible patients, without delay

@gcfmd @JavedButler1 @DCRINews @JAMACardio

https://t.co/OsmCRZXMcK…

[Giuseppe Maltese @docmaltese]

"Because the rise in obesity is forecasted to continue throughout the world, political commitment to transform the diets of all children and adolescents within sustainable global food systems is now urgent".

@ShivaniM_KC @DrDita @SaimeFulya

https://t.co/ilDoYXMego

[Giuseppe Maltese @docmaltese]

Use of SGLT2i and concern about muscle mass in older people.

https://t.co/AttRao9B7Y

[Prof Kamlesh Khunti @kamleshkhunti]

SGLT2 inhibitors associated with a lower risk of atrial arrythmia and SCD in people with T2 diabetes and/or heart failure or chronic kidney disease.

A meta-analysis of 38 randomized controlled trials

https://t.co/rZPnKsVACK

[Steve Greene @SJGreene_md]

3 Pillars of Medical Therapy for HFmrEF/HFpEF

*⃣ SGLTi + nsMRA + GLP-1 RA (if obesity) *⃣

The optimal strategy is simultaneous or rapid sequence initiation to all eligible patients, without delay.

@gcfmd @JavedButler1 @DCRINews @JAMACardio

https://t.co/yNDUGCJw4P